skip to contents
The wishful new year 2017 has dawned upon us.
I would like to make an inaugural greeting as a new Chief Director of KALC, wishing you a prosperous year, hoping that the pending national crisis will be overcome and that our Association will take a new leap forward.
In recent years, the lung cancer treatment has reached a remarkable level in academic and clinical aspects and has emerged as a major concern in terms of industry and national economy. The clinical introduction of next-generation targeted anticancer agents (EGFR-TKI and ALK inhibitors) and immune-checkpoint inhibitors have been established as a new paradigm in the treatment of lung cancer.
The companion diagnotics has also become an important issue, and I am sure that it is not so long before the health insurance would benefits for the NGS panel. Lung cancer now draws much more attentions in the academic, clinical and socio-economic fields than at any other eras and it is no exaggeration to say that lung cancer is at the center of transition from the evidence based medicine to the precise medicine era, which makes me feel a heavy responsibility.
In this context, I would like to share following projects for the next two years.
First, I will hold international academic conferences to enhance the prestige of our Association and to keep up with globalization. Specifically, I will open the Korean Lung Cancer Conference (KLCC) in Seoul in early September 2018. The conference is planned to be held every two years and then every year, if conditions permit.
Second, I will publish "Report of Current Situation of Domestic Lung Cancer" every year, which can be used not only as an academic resources but as a guide to the government's policy on lung cancer.
Third, I will focus on academic and social promotion of "non-smoking women with lung cancer". Indeed, smoking is considered to be a major cause of lung cancer, but I will attract social attention to a continuous increase in the lung cancer from female non-smokers led by EGFR oncogenic mutations and their clinical and academic importance in South Korea.
Fourth, in order to let our society know that the lung cancer at the center of precision medicine, I will hold a lecture on lung cancer precise medicine workshop which will network medical researchers, clinical researchers, basic medical scientists, and researchers of life-science related companies.
make known that lung cancer is in the center of precision medicine, a recent general trend of medicine, and will enable our Association to play a pivot role by organizing workshops for lung cancer precision medicine that lead to the networking of clinical doctors, basic scientists, biomedical corporation researchers etc.
I would like to express my sincere gratitude to all of you for kind attention and cooperation in these activities that I am preparing at the conference. I wish you healthier and wishful things in the New Year.